Results 101 to 110 of about 280,456 (250)

Rheocarna treatment for non‐dialysis patients

Therapeutic Apheresis and Dialysis, Volume 29, Issue 4, Page 588-592, August 2025.
Abstract Introduction Rheocarna has attracted attention as an alternative therapy for severe chronic limb‐threatening ischemia, and there have been reports of its usefulness. However, most of these reports have been on dialysis patients, and there are few reports on the treatment conditions and efficacy in non‐dialysis patients.
Atsushi Ohkubo, Takatoshi Sakurasawa, Yuki Hoshikawa, Masaya Deushi, Mana Usui, Shigeto Komori, Ayako Itagaki, Hiroko Yamamoto, Hiroshi Seshima, Naoki Kurashima, Soichiro Iimori, Shotaro Naito   +11 more
wiley   +1 more source

Aggressive lipid-lowering therapy before and after revascularization in patients with stable coronary artery disease

Медицинский совет, 2013
The review presents data on the effectiveness of lipid profile correction with maximum doses of statins, primarily atorvastatin, and lipoprotein apheresis.
R. N. Adzhiev, M. S. Safarova, M. V. Yezhov, Y. G. Matchin   +3 more
doaj   +1 more source

Low-density lipoprotein cholesterol lowering therapies: what is on the horizon? [PDF]

, 2015
Elevated low-density lipoprotein cholesterol (LDL-C) levels are associated with an increased risk for cardiovascular disease (CVD). Statins have been the cornerstone of lipid therapy to lower LDL-C for the past two decades, but despite significant ...
Figueredo, M.D., Vincent M, Gadi, Ramprasad   +1 more
core   +1 more source

Coronary Plaque Characteristics Assessed by Optical Coherence Tomography and Plasma Lipoprotein(a) Levels in Patients With Acute Coronary Syndrome

Catheterization and Cardiovascular Interventions, Volume 106, Issue 1, Page 64-72, July 1, 2025.
ABSTRACT Background Lipoprotein(a) [Lp(a)] is associated with increased cardiovascular risk, but its influence on plaque characteristics at optical coherence tomography (OCT) evaluation is not fully understood. Aims This study seeks to explore the impact of Lp(a) levels on plaque morphology as assessed by OCT in a very high‐risk subset of patients ...
Francesca Maria Di Muro, Maria Federica Crociani, Giulia Nardi, Niccolo' Ciardetti, Lucrezia Biagiotti, Elisa Bigi, Francesco Meucci, Miroslava Stolcova, Francesca Ristalli, Emanuele Cecchi, Iacopo Muraca, Renato Valenti, Carlo Di Mario, Alessio Mattesini   +13 more
wiley   +1 more source

On the Road to Accurate Biomarkers for Cardiometabolic Diseases by Integrating Precision and Gender Medicine Approaches [PDF]

, 2019
The need to facilitate the complex management of cardiometabolic diseases (CMD) has led to the detection of many biomarkers, however, there are no clear explanations of their role in the prevention, diagnosis or prognosis of these diseases.
Argano, Vincenzo, Balistreri, Carmela Rita, Giarratana, Rosa Maria, Lio, Domenico, Scola, Letizia, Torre, Salvatore   +5 more
core   +1 more source

Single Low-Density Lipoprotein Apheresis Does Not Improve Vascular Endothelial Function in Chronically Treated Hypercholesterolemic Patients

International Journal of Vascular Medicine, 2016
Objective. To investigate vascular endothelial function (VEF) responses to a single low-density lipoprotein (LDL) apheresis session in hypercholesterolemic patients undergoing chronic treatment. Methods. We measured brachial artery flow-mediated dilation
Kevin D. Ballard, Eunice Mah, Yi Guo, Richard S. Bruno, Beth A. Taylor, Jo Ellen Beam, Donna M. Polk, Paul D. Thompson   +7 more
doaj   +1 more source

Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study

Journal of Cardiovascular Pharmacology and Therapeutics, 2020
Aim: We evaluated the lipid-lowering (LL) effect of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in patients with heterozygous familial hypercholesterolemia (HeFH) treated with LL-drugs and lipoprotein apheresis (LA).
V. Kolovou, N. Katsiki, S. Makrygiannis, Sophie Mavrogieni, N. Karampetsou, A. Manolis, A. Melidonis, D. Mikhailidis, G. Kolovou   +8 more
semanticscholar   +1 more source

Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia [PDF]

, 2017
Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction ...
Bray, Sarah, Bridges, Ian, Cheng, Lung-I, Dent, Ricardo, Deshpande, Sohan, Forbes, Carol A., Gandra, Shravanthi R., Kleijnen, Jos, Ross, Janine, Sattar, Naveed, Stroes, Erik S.G., Toth, Peter P., Worth, Gavin M., Worthy, Gillian   +13 more
core   +1 more source

コウテンセイ シケツ イジョウ オ ガッペイ シ low density lipoprotein アフェレーシス セコウジ オヨビ シキュウ ケイブ セイケンジ ニ シケツ コンナンナ セイキ シュッケツ オ キタシタ カゾクセイ コウコレステロール ケッショウ ガッペイ シキュウケイガン ノ イチレイ [PDF]

, 2015
今回我々は、家族性高コレステロール血症（FH）を合併し、low density lipoprotein（LDL）アフェレーシス後に不正性器出血を繰り返した臨床的に子宮頸癌と診断した症例を経験したので報告する。症例は49 歳、未経妊の女性。既往歴として、FH の他、心血管系疾患の術後治療として、ワーファリンとアスピリンを内服していた。LDL アフェレーシス後に、大量の不正性器出血を主訴に当院へ救急搬送された。腟鏡診では子宮腟部に明らかな腫瘍を認めなかったが、magnetic resonance ...
永瀬 智, 渡邉 憲和, 高橋 俊文   +2 more
core   +1 more source

How periodontal disease may contribute to cardiovascular disease [PDF]

, 2000
No abstract ...
Kinane, D.F., Lowe, G.D.O.
core   +1 more source